Dhawaan, Nantong Chanyoo wuxuu sameeyay taariikh kale oo muhiim ah!Dedaalladii socday in ka badan hal sano, KDMF-gii ugu horreeyay ee Chanyoo waxaa oggolaaday MFDS.Sida soo saaraha ugu weyn ee Rosuvastatin Calcium ee Shiinaha,waxaan rabnaa inaan bog cusub ka furno suuqa Kuuriya.Iyo badeecooyin badan ayaa la soo saari doonaa sanadaha soo socda.

Sidoo kale, waxaad tixraaci kartaa oo aad ka heli kartaa macluumaadkayaga mareegahan:

https://nedrug.mfds.go.kr/pbp/CCBAC03

Kaalshiyamka Rosuvastatin waxay ku habboon tahay daaweynta adjuvant ee bukaannada qaba hypercholesterolemia aasaasiga ah (nooca IIa, oo ay ku jiraan heterozygous familial hypercholesterolemia) ama lipemia isku dhafan (nooca IIb) marka cuntada ama daaweynta jimicsiga aysan ku habboonayn.Kaalshiyamka Rosuvastatinwaa 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor oo la xushay.Iyada oo la joojinayo HMG-CoA reductase, waxay yaraynaysaa abuurka unugyada beerka iyo kaydinta kolestaroolka, taas oo hoos u dhigta wadarta guud ee kolestaroolka (TC) iyo heerarka kolestaroolka lipoprotein-cufnaanta hoose (LDL-C).

Sida laga soo xigtay xogta Newport, laga bilaabo Juun 30, 2018 ilaa Juun 30, 2019, iibka caalamiga ah ee diyaarinta calcium rosuvastatin wuxuu ahaa US $ 3.461 bilyan, hoos u dhac sanadle ah oo ah 13%;Iibka caalamiga ah ee alaabta ceeriin ee kaalshiyamka ee rosuvastatin wuxuu ahaa 151.09 tan, koror sanadle ah oo ah 14%

Anaga,Warshada Dawooyinka ee Changzhou(saaraha hoosaadka: Nantong Chanyoo Pharmatech Co., Ltd.) waxaan nafteena u huray alaab-qeybiyaha ugu weyn ee Rosuvastatin API.